Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities
Current evidence supports continued investigation of semaglutide as a potential neuroprotective strategy, while highlighting the need for earlier intervention studies, improved understanding of CNS target engagement, and further clinical validation.
A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...
Dipesh Kumar, Renuka Sahu, Naveen Kumar et al.· International Journal of Sci...· 0 citations
Abstract Background Neurodegenerative disorders, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), present substantial global health challenges due to a lack of disease-modifying therapies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), traditionally used in type 2 diabetes management, have em...
Paulina Orzechowska, Gabriela Budziszewska, Aneta Dziurdź et al.· Biuletyn Głównej Biblioteki...· 0 citations
Alzheimer’s Disease (AD) is a neurodegenerative disorder with
progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress,
and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by
the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...
Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al.· Future Medicinal Chemistry· 0 citations
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular deposition of amyloid-β (Aβ), intracellular hyperphosphorylation of microtubule-associated protein tau and chronic neuroinflammation. At present, effective disease-modifying therapies for AD remain limited. Dexmedetomidine (Dex),...
Jun Kang, Yong-Bo Duan, Jia-Xuan Bi et al.· Frontiers in Aging Neuroscie...· 0 citations
Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons, mitochondrial dysfunction, oxidative stress, and persistent neuroinflammation. Recent findings suggest that impaired glucose metabolism and disrupted energy balance may play a role in the early stages of the dis...
Sivakumar G., Thilagavathi K., Narmatha K. K. et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
